Figure 6.

The PDZ Ligand of GluK2 Is Involved in Both Basal and Activity-Dependent Progression of KARs through the Secretory Pathway

(A) Representative images of HeLa cells showing the distributions of exogenously expressed SBP-EGFP-GluK2-ETMA or SBP-EGFP-GluK2-EPAS before and 30 min after addition of biotin. In all cases, EGFP was used to visualize total receptors, and surface-expressed KARs were visualized by live labeling with anti-SBP antibody.

(B) Quantification of two independent experiments; n = 40 for 0 and n = 80 for 30. p > 0.05, Welch’s t test. See also Figure S6A.

(C) Representative images of hippocampal neurons expressing SBP-EGFP-GluK2-ETMA or SBP-EGFP-GluK2-EPAS 24 hr after addition of biotin. EGFP was used to visualize total receptors, and surface-expressed KARs were visualized by live labeling with anti-SBP antibody.

(D) Quantification of three independent experiments; n = 22–24. p > 0.05, Welch’s t test.

(E) Representative images of hippocampal neurons expressing SBP-EGFP-GluK2-ETMA or SBP-EGFP-GluK2-EPAS before or 30 min after addition of biotin, with or without a transient 5-min pre-treatment of 10 μM kainate. EGFP was used to visualize total receptors, and surface-expressed KARs were visualized by live labeling with anti-SBP antibody. See also Figure S6B.

(F) Quantification of four independent experiments; n = 21–32. ^∗∗∗∗p < 0.0001, ^∗∗∗p < 0.001, Welch’s t test.

Scale bars, 10 μm.